Progressive supranuclear palsy (PSP) is a rare brain disorder that can affect balance, movement, walking, and stiffness. Because PSP can share some symptoms with Parkinson’s disease, it can sometimes be difficult to diagnose.
Currently, there is no cure for PSP and no approved treatment that slows or stops the progression of the disease. Clinical research is an important part of finding potential new treatments.
The PSP Trial Platform (PTP) study is a multicenter Phase 2 clinical trial designed to test multiple investigational treatments for people living with mild-to-moderate PSP.
The study uses a randomized, double-blind, placebo-controlled platform design. This means participants are randomly assigned to receive one of several investigational treatments or placebo, and neither participants nor study staff know which treatment a participant is receiving during the blinded portion of the study.
The primary goal of the study is to determine whether one or more investigational treatments may affect the progression of PSP and whether they are safe and well-tolerated.
The study is looking for adults who:
All participants must have a study partner, who has at least weekly contact with them, who can accompany them to study visits.
Interested participants can contact the Memory and Aging Program Outreach Team at (401) 455-6402 or by sending an email to memory@butler.org to discuss additional eligibility criteria.